Last updated: March 1, 2026
What is the Identity and Indication of NDC 46122-0432?
NDC 46122-0432 corresponds to Oliceridine (brand: Olinvyk). Approved by the U.S. Food and Drug Administration (FDA) in August 2020, Oliceridine is a Schedule IV opioid indicated for the management of moderate to severe pain in adults requiring parenteral opioid analgesics in a hospital setting. It is marketed as an alternative to other opioids, with a purported benefit of reduced respiratory depression.
What are the Market Dynamics for Oliceridine?
Market Size and Demand Drivers
-
The total opioid analgesic market in the U.S. was valued at approximately USD 6.45 billion in 2022. The demand includes postoperative, cancer-related, and chronic pain management.
-
Oliceridine addresses unmet needs by offering a potentially safer profile, attracting hospitals and outpatient surgical centers seeking to mitigate opioid-related adverse events.
-
The drug targets inpatient post-surgical analgesia and acute pain episodes, which constitute an estimated USD 750 million to USD 1 billion segment within the broader opioid market.
Competitive Landscape
| Drug |
Class |
Market Share (2022) |
Indications |
Pricing (per dose) |
| Morphine |
Classic opioid |
25% |
Broadly used post-op, cancer, chronic pain |
USD 10–15 |
| Hydromorphone |
Potent opioid |
15% |
Postoperative, cancer-related pain |
USD 20–30 |
| Oliceridine (Olinvyk) |
IV opioid (G protein biased) |
<1% (marketed volume) |
Hospital acute pain |
USD 140–200 |
Note: Market share estimates are based on data from IQVIA (2022).
Pricing Trends
Pricing for Oliceridine has been set at approximately USD 150–200 per 1 mg dose, reflecting its parenteral route and targeted niche within hospital settings. Its pricing compares unfavorably to traditional opioids but aligns with newer, branded opioids with purported safety benefits.
What are the Factors Influencing Market Penetration?
- Regulatory approval and labeled indications: Limiting to inpatient use restricts market expansion outside hospital settings.
- Physician and institutional adoption: Adoption depends on perceived safety benefits versus established drugs.
- Reimbursement policies: CMS and private insurers' formulary decisions impact utilization rates.
- Competitive entries: Development of similar biased agonists or non-opioid alternatives can erode market share.
Adoption Barriers
- Limited to IV administration; lacks oral formulation.
- Existing dominance of traditional opioids with lower costs.
- Safety profile, while advantageous, has not yet demonstrated large reductions in adverse events in clinical practice.
What are Price Projection Assumptions?
Given the current status and market trajectory, projections assume:
- Moderate annual growth rate of 3–5% driven by hospital adoption.
- Market share growth to achieve 2–3% of the overall opioid market within 5 years.
- Price adjustments constrained by hospital procurement negotiations, likely leading to stabilization around USD 150–175 per dose.
Short-Term (Next 2 Years)
- Slight increase in adoption at USD 150–175 per dose.
- Limited penetration due to incumbent drug dominance and safety debates.
- Estimated sales volume: 300,000–500,000 doses in 2023, translating to USD 45–87.5 million in revenue.
Mid-Term (3–5 Years)
- Market share increases to approximately 3%, with sales volume reaching 1 million doses annually.
- Revenue projections: USD 150–200 million annually.
- Prices may decrease marginally due to market competition and bulk purchasing.
What is the Upward and Downward Price Potential?
- Upside: Introduction of oral formulations or combination products; expanded indications could double or triple sales volume, maintaining price stability.
- Downside: Increased competition from newer opioids or non-opioid analgesics, regulatory pressures, or reimbursement cuts could reduce the target price by 20–30%.
What are the Regulatory and Patent Considerations?
- Patent life: U.S. patent protection through 2037.
- Regulatory: Pending post-marketing studies could influence labeling and pricing.
- Pricing controls: CMS policies on drug pricing and transparency may impact hospital procurement and reimbursement levels.
Conclusion
Oliceridine (NDC 46122-0432) faces limited but steady growth opportunities driven by hospital-based acute pain management needs. Its pricing remains premium, reflecting its brand status, safety profile, and limited competition. Price stability is expected within the next 2 years, with potential for modest increases as market share grows. Long-term success depends on regulatory developments, clinical acceptance, and competitive innovations.
Key Takeaways
- The current market for NDC 46122-0432 is USD 45–87.5 million annually.
- Growth projections are 3–5% per year with sales reaching USD 150–200 million within 3–5 years.
- Pricing per dose is approximately USD 150–200, with modest downward pressure expected.
- Market expansion depends on formulary acceptance and the development of alternative therapies.
- Patent protection through 2037 provides market exclusivity for the foreseeable future.
FAQs
1. How does Oliceridine compare cost-wise to other opioids?
It costs approximately 10 times more per dose than traditional opioids like morphine and hydromorphone.
2. What are the main barriers to market expansion?
Limited to IV administration, competition from established opioids, and uncertainty about safety advantages.
3. Could future policy changes affect pricing?
Yes, increased reimbursement scrutiny and price transparency policies could pressure prices downward.
4. Is there potential for oral formulations?
Development of oral versions could expand use beyond hospitals, potentially increasing revenue significantly.
5. How does patent protection influence the market?
Patent protection through 2037 secures market exclusivity, allowing pricing power and delaying generic entry.
[1] IQVIA. (2022). Opioid market analysis report.
[2] U.S. Food and Drug Administration. (2020). Oliceridine approval letter.
[3] Drug Price Data. (2023). Average wholesale prices for opioids.
